Estratégias de conversão em metástases hepáticas colorretais do tipo selvagem RAS: uma revisão sistemática e metanálise de ensaios de primeira linha comparando regimes com inibidores do receptor do fator de crescimento antiepidérmico versus bevacizumab

Resumo original em inglês

O que aconteceu

The selection of optimal conversion therapy for patients with initially unresectable colorectal liver metastases (CRLM) remains a significant clinical challenge. In patients with RAS wild-type disease, a key therapeutic decision involves whether to combine chemotherapy with an EGFR inhibitor (EGFRi) or bevacizumab. A systematic literature review and meta-analysis of randomised controlled trials (RCTs) published between 2015 and 2025 were conducted to compare chemotherapy plus either an EGFRi or bevacizumab as first-line treatment for patients with RAS wild-type metastatic colorectal cancer and liver-limited disease. Analyses encompassed both the overall population and subgroups defined by primary tumor location (PTL). Six RCTs, including data from 795 patients with CRLM, were identified. No statistically significant differences were found between EGFRi- and bevacizumab-based regimens for progression-free survival (PFS) and overall survival (OS). Four studies contributed to analyses of response rate (RR) and complete (R0) resection rate, while three studies contributed to the depth of response (DpR) analysis. EGFRi-based regimens demonstrated statistically significant improvements in both RR and DpR, with pooled odds ratios (ORs) of 1.98 and 1.70, respectively. No statistically significant difference in R0 resection rates was observed. Subgroup analyses by PTL revealed no statistically significant survival advantage for either agent in either left- or right-sided subgroups. This comprehensive meta-analysis identified no significant survival advantage for either anti-EGFRs or bevacizumab in patients with initially unresectable RAS wild-type CRLM. Further research is warranted to elucidate why the increased and deeper responses observed with anti-EGFRs do not result in higher R0 resection rates or improved survival.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.